Article Figures & Data
Figures
- Fig. 1.
Difference from mean for fluconazole log-MIC (reading at 48 h). The horizontal line indicates d̅.
- Fig. 2.
Trends of fluconazole MICs for C. albicansstrains isolated sequentially from five AIDS patients undergoing azole therapy (readings at 48 h). Outcomes of fluconazole therapy are abbreviated as follows: R, response to 100 to 200 mg/day; PR, partial response to 200 mg/day; F, failure to respond to 200 to 400 mg/day. Vertical lines indicate the start of failure of fluconazole therapy.
- Fig. 3.
Distribution of itraconazole and ketoconazole MICs for 47 strains of C. albicans obtained by BM (A and B) and AD-Cas (C and D). Shaded bars represent the distributions of itraconazole and ketoconazole MICs for fluconazole-susceptible isolates (fluconazole MICs, ≤4.0 and ≤32 μg/ml by BM and AD-Cas, respectively); open bars represent the distributions of itraconazole and ketoconazole MICs for fluconazole-resistant isolates (fluconazole MICs, ≥8.0 and ≥64 μg/ml by BM and AD-Cas, respectively). When the Mann-Whitney U test was applied to determine the distribution of itraconazole and ketoconazole MICs for the two groups of isolates, a statistically significant difference was found with both the methods employed (P = 0.0001).
Tables
- Table 1.
Fluconazole, itraconazole, and ketoconazole MICs for 47 clinical isolates of C. albicans obtained by three methods
Method Time of reading (h) MIC (μg/ml) ofa: Fluconazole Itraconazole Ketoconazole Range 50% 90% Range 50% 90% Range 50% 90% BM 48 0.125–32 4.0 16 0.03–0.5 0.125 0.25 0.03–0.5 0.06 0.25 AD-Cas 24 1.0–>64 32 >64 0.03–2.0 0.125 0.25 0.03–0.5 0.125 0.25 48 1.0–>64 32 >64 0.03–2.0 0.125 2.0 0.03–0.5 0.125 0.5 AD-RPMI 24 0.25–>64 16 >64 0.03–>8.0 0.125 >8.0 0.03–8.0 0.125 0.25 48 8.0–>64 >64 >64 0.125–>8.0 >8.0 >8.0 0.03–>8.0 8.0 >8.0 Etest-Cas 24 0.5–>256 32 128 0.03–12 1.0 4.0 0.008–0.5 0.125 0.25 48 1.0–>256 64 128 0.06–12 2.0 8.0 0.008–0.75 0.25 0.5 Etest-RPMI 24 0.125–>256 16 >256 0.08–>16 1.0 >16 0.008–>32 0.25 0.5 48 8.0–>256 128 >256 0.08–>16 2.0 >16 0.008–>32 0.5 >32 ↵a 50% and 90%, MICs at which 50 and 90% of the isolates are inhibited, respectively.
- Table 2.
Agreement of MICs obtained by AD and by Etest with MICs obtained by NCCLS BM
Method Time of reading (h) Fluconazole MICs Itraconazole MICs Ketoconazole MICs d̅ % Agreementa d̅ % Agreementa d̅ % Agreementa ±1 Dil ±2 Dil ±1 Dil ±2 Dil ±1 Dil ±2 Dil AD-Cas 24 2.6 72 98 0.32 79 98 0.16 98 100 48 3.0 91 100 0.79 74 96 0.57 83 100 AD-RPMI 24 2.5 49 83 2.1 23 70 0.07 75 84 48 4.8 45 64 5.8 34 57 4.8 23 25 Etest-Cas 24 4.0 62 91 3.5 49 85 0.27 98 98 48 3.5 64 94 3.6 51 87 0.5 96 100 Etest-RPMI 24 2.5 26 81 3.9 43 60 2.6 26 51 48 5.0 45 64 4.5 23 43 4.3 6 20 ↵a % of agreement within 1 or 2 dilutions (Dil) referred to d̅.
